Early evidence suggests GLP-1s were linked to lower risks of developing substance use disorders — from alcohol to opioids — and to fewer overdoses and deaths in people with existing addictions.

All-cause mortality significantly lower with GLP-1 RA use, with consistent benefit across major cancer types, most GLP-1 RA types.

For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the weight loss approach that better addresses their arrhythmia, observational data suggested.

Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...

GLP-1 RAs for weight loss appear to be similarly effective among adults across ages, races, and starting weights.

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

Among patients eligible for MBS, GLP-1 RA prescriptions increased from 2018 to 2025, while MBS use decreased beginning in 2023.

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity. At the heart of ...

Opportunities in the GLP-1 receptor agonist market include the development of new diabetes and obesity treatments with high ...

Results showed that use of GLP-1 receptor agonists did not increase short-term medical or surgical complications among ...

Though the first GLP-1 agonists date back more than 20 years, it's only in the last couple of years that they began to dominate the pharmaceutical space for their massive potential as weight loss ...